Hydroxychloroquine Blood Concentrations and Effects in Chinese Patients with IgA Nephropathy

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Jul 24

PMID 39048780

Authors

Ting Yang

Yaotong Shi

Ye Wang

Yuan Feng

Qiuyuan Shao

Chunming Jiang

Lulu Wang

Jing Liu

Affiliations

Soon will be listed here.

Abstract

Background: Hydroxychloroquine (HCQ) is recommended for Chinese patients with immunoglobulin A nephropathy (IgAN). However, the relationship between HCQ blood concentration and the therapeutic effect for IgAN has not yet been defined. This study investigates the optimal and efficacious range of HCQ blood concentrations in Chinese patients with IgAN.

Methods: Seventy-three patients with biopsy-proven IgAN who were at risk of progression were included in this study. Thirty-eight patients with IgAN were treated with HCQ plus an optimized renin-angiotensin-aldosterone system inhibitor (RAASi), and thirty-five patients received only RAASi. Blood HCQ concentration and 24-h proteinuria were examined at three and six months after treatment.

Results: The baseline proteinuria levels were comparable between the RAASi and HCQ groups. The HCQ group had lower 24-h proteinuria than the RAASi group three months after treatment, though the difference was not significant (p = 0.38). After six months, the median proteinuria level was significantly lower in the HCQ group than in the RAASi group (p < 0.05). The percentage reduction in 24-h proteinuria in the HCQ group was greater than that in the RAASi group at three (p < 0.05) and six months (p < 0.05). Hydroxychlorquine blood concentration and efficacy were positively correlated at three months (r = 0.428, p < 0.05) and six months (r = 0.48, p < 0.05). Moreover, the optimal blood concentration of HCQ for three-month efficacy was 418.96 ng/mL and that for six-month efficacy was 582.48 ng/mL. No serious adverse events were reported during HCQ treatment.

Conclusions: Hydroxyhloroquine safely reduces proteinuria in Chinese patients with IgAN. The efficacy of HCQ is positively correlated with its blood concentration.

References

Tang C, Lv J, Shi S, Chen Y, Liu L, Zhang H . Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. J Nephrol. 2021; 35(2):429-440. DOI: 10.1007/s40620-021-00988-1. View

Durcan L, Clarke W, Magder L, Petri M . Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015; 42(11):2092-7. PMC: 4630115. DOI: 10.3899/jrheum.150379. View

Restrepo J, del Rincon I, Molina E, Battafarano D, Escalante A . Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. J Clin Rheumatol. 2017; 23(3):144-148. PMC: 5364043. DOI: 10.1097/RHU.0000000000000502. View

Yang Y, Chen P, Liu L, Cai Q, Shi S, Chen Y . Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. 2019; 20(1):297. PMC: 6683466. DOI: 10.1186/s12882-019-1488-6. View

Al-Rawi H, Meggitt S, Williams F, Wahie S . Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus. 2017; 27(5):847-852. DOI: 10.1177/0961203317727601. View

Tett S, Cutler D, Beck C, Day R . Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study. J Rheumatol. 2000; 27(7):1656-60. View

Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J . Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2017; 77(1):98-103. DOI: 10.1136/annrheumdis-2017-211836. View

Marmor M, Kellner U, Lai T, Melles R, Mieler W . Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6):1386-94. DOI: 10.1016/j.ophtha.2016.01.058. View

Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V . Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67(8):2176-84. DOI: 10.1002/art.39194. View

10.

Liu L, Yang Y, Shi S, Bao Y, Yang C, Zhu S . Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019; 74(1):15-22. DOI: 10.1053/j.ajkd.2019.01.026. View

11.

Biswas M, Sukasem C . Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications. Pharmacogenomics. 2023; 24(15):831-840. DOI: 10.2217/pgs-2023-0124. View

12.

Dima A, Jurcut C, Arnaud L . Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. Joint Bone Spine. 2021; 88(3):105143. DOI: 10.1016/j.jbspin.2021.105143. View

13.

Rodrigues J, Haas M, Reich H . IgA Nephropathy. Clin J Am Soc Nephrol. 2017; 12(4):677-686. PMC: 5383386. DOI: 10.2215/CJN.07420716. View

14.

Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns T . Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. Nephrol Dial Transplant. 2017; 33(9):1604-1610. PMC: 7170714. DOI: 10.1093/ndt/gfx318. View

15.

Inker L, Schmid C, Tighiouart H, Eckfeldt J, Feldman H, Greene T . Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367(1):20-9. PMC: 4398023. DOI: 10.1056/NEJMoa1114248. View

16.

Tang C, Lv J, Shi S, Chen Y, Liu L, Zhang H . Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. BMC Nephrol. 2020; 21(1):469. PMC: 7653892. DOI: 10.1186/s12882-020-02141-9. View

17.

Stefan G, Mircescu G . Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail. 2021; 43(1):1520-1527. PMC: 8604447. DOI: 10.1080/0886022X.2021.2000875. View

18.

Rainsford K, Parke A, Clifford-Rashotte M, Kean W . Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015; 23(5):231-69. DOI: 10.1007/s10787-015-0239-y. View

19.

Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y . Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy. Kidney Int Rep. 2017; 2(4):603-609. PMC: 5678641. DOI: 10.1016/j.ekir.2017.02.003. View

20.

Garg S, Unnithan R, Hansen K, Costedoat-Chalumeau N, Bartels C . Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020; 73(5):707-716. DOI: 10.1002/acr.24155. View